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Abstract
Background:  Most of the studies about invasive Candida  infections in cancer patients have focused on
haematological patients. The aim of this study was to provide information about risk factors for candidaemia in
patients with solid tumours.
Methods: Retrospective cohort study. During a 9-year period (1995–2003) we reviewed all cases of candidaemia
that affected cancer patients in Santa Casa Complexo Hospitalar, Brazil.
Results: During the period of study, 210 patients had the diagnosis of candidaemia in our medical centre, and 83
of these patients had cancer (39.5%). The majority of patients with cancer had solid tumours (77.1%), mostly in
the alimentary tract. Most of solid cancers were non-metastatic (71.9%). Major diagnoses in patients with
haematological neoplasia were acute leukaemia (n = 13), high grade non-Hodgkin lymphoma (n = 5) and Hodgkin's
disease (n = 1). Non-Candida albicans species caused 57.8% of the episodes of candidaemia in patients with cancer,
mainly in patients with haematological malignancies (p = 0.034). Neutropenia and treatment with corticosteroids
were more frequent in the haematological group, in comparison with patients with solid tumours. Only 22.2% of
patients with solid tumours were neutropenic before candidaemia. Nonetheless, the presence of ileus and the use
of anaerobicides were independent risk factors for candidaemia in patients with solid cancers. The overall
mortality in cancer patients with candidaemia was 49.4%. We then compared 2 groups of adult patients with
candidaemia. The first was composed of non-neutropenic patients with solid tumours, and the second group
included patients without cancer. We found that central venous catheters and gastrointestinal surgery were
independently associated with candidaemia in patients with solid tumour.
Conclusion: Cancer patients with candidaemia seem to have very different predisposing factors to acquire the
infection when stratified according to baseline diseases. This study provides some useful clinical information
regarding risk for candidaemia in patients with solid tumours.
Background
Most of the knowledge about invasive Candida infections
in cancer patients has derived from patients with haema-
tological malignancies [1], and data regarding risk factors
in patients with solid tumours are sparse [2,3]. The pur-
pose of this study was to compare the demographic fea-
tures, risk factors, and aetiology of candidaemia amongst
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patients with solid tumours and those with haematologi-
cal neoplasms in our medical centre over the last 9 years.
Methods
A retrospective cohort study was performed in Santa Casa
Complexo Hospitalar, a 1,200-bed Brazilian tertiary
teaching hospital. During the period comprising 1995 to
2003, all patients with cancer who developed candidae-
mia were included in the study. Candidaemia was defined
as the presence of at least one positive blood culture for
Candida obtained from a peripheral vein in a patient with
associated signs and symptoms temporally related [2].
The episode of candidaemia was considered outpatient-
acquired if had occurred prior to or within 72 h of hospi-
tal admission [4]. Candidaemia in patients who had
undergone major surgical procedures in the last 30 days or
prosthesis insertion in the last year was considered to be
nosocomial. Medical charts of these patients were
reviewed to record clinical and demographic characteris-
tics presented in the period of 30 days before the collec-
tion of the first positive blood sample for Candida.
Patients were considered paediatrics if their age was ≤ 13
years-old [5]. Neutropenia was defined as an absolute
neutrophils count < 1,000 cells/mm3. Breakthrough can-
didaemia was defined as the occurrence of candidaemia in
a patient receiving at least 3 days of systemic antifungal
therapy [6]. The protocol was approved by the hospital
independent ethics committee (protocol 547/02). Due to
the nature of this study there was no need to apply
informed consent to patients.
Blood samples were processed with BacT/Alert™ auto-
mated system or lysis centrifugation (Isolator™). Only one
isolate was included per patient (the first one). Germ
tubes were performed, and negative strains were identified
through kit ID 32C (BioMerieux, France).
Statistical analysis
Descriptive statistics were used to summarize the data.
Pearson's chi-square and Fisher's exact test were used to
evaluate the association between qualitative variables,
and Mann-Whitney test was used for the comparison of
quantitative variables, with a bilateral level of significance
of 5%. We used univariate analysis to identify candidate
variables to include in the binary logistic regression
model. A stepwise forward selection (Wald) logistic
regression procedure was used to derive the model. We
included only variables that showed a Wald test > 2 and a
p-value < 0.25 in the univariate analysis [7]. Potential con-
founding variables were tested in multivariate analyses; if
they changed the estimate of the association of interest,
they remained in the final model. An important step in
the process of modelling a set of data was determining
whether or not there was evidence of interaction. Odds
ratios with 95% confidence intervals were calculated.
Data analysis was performed with the statistical software
package SPSS version 10.0.
Results
During the period of study, 210 patients had the diagnosis
of candidaemia in our medical centre, and 83 of these
patients had cancer (39.5%). The majority of these cancer
patients were male (55.4%), and median age was 50.2
years old (range, 0.7–81.3 years old). Candidaemia in
cancer patients was largely a nosocomial infection
(89.2%).
Most of the patients with cancer had solid tumours
(77.1%, n = 64). Most of the solid tumours affected the
alimentary (36.0%, n = 23), genitourinary (20.4%, n =
13), and gynaecological tracts (18.8%, n = 12). Colon can-
cer was the most prevalent neoplasm (9.5%, n = 6).
Uncommon cancers included tumours affecting the respi-
ratory system (9.4%, n = 6) and sarcomas (4.8%, n = 3).
Most of solid cancers were locally advanced (35.9%, n =
23), 31.3% were restricted to the affected organ (n = 20),
and only 28.1% were metastatic (n = 18). Three patients
(4.7%) had had complete response to treatment.
Major diagnoses in the group of patients with haemato-
logical neoplasia were acute leukaemia (68.4%, n = 13),
high grade non-Hodgkin lymphoma (26.3%, n = 5) and
Hodgkin's disease (5.3%, n = 1). Most of the patients with
leukaemia were receiving induction or consolidation
chemotherapy (61.6%, n = 8), 30.8% had progressive or
resistant disease (n = 4), and 7.7% were in remission (n =
1). The patients with lymphoma were distributed in stages
I or II disease (50.0%, n = 3) and stages III or IV (50.0%,
n = 3).
The median number of positive blood cultures in cancer
patients was 2 (range, 1–5) and median duration of can-
didaemia was 1.0 day (range, 1–20 days). Species other
than Candida albicans were the aetiology of 57.8% of can-
didaemias in cancer patients, mainly C. parapsilosis
(27.7%) and C. tropicalis (13.3%). C. glabrata and C. krusei
were infrequent (3.6% each). Breakthrough candidaemia
accounted for 9.6% of episodes (n = 8). Previous bacterae-
mia occurred in 32.5% (n = 27), mainly caused by gram-
positive aerobic organisms (n = 16). Candida was isolated
in sites other than blood in 34.9% of patients (n = 29),
mainly from catheters (20.5%, n = 17), and urine (18.1%,
n = 15). Concomitant bacteraemia occurred in 18.1% of
cancer patients with candidaemia (n = 18). Central
venous catheters (CVCs) were removed for 69.2% of can-
cer patients who had catheters at the moment of candi-
daemia, and median time for catheter removal was 5.0
days. Fundoscopic eye examination was performed for
only 1 patient (1.2%). Systemic antifungal treatment was
used in 75.9% of patients (n = 63), mostly amphotericinBMC Infectious Diseases 2006, 6:50 http://www.biomedcentral.com/1471-2334/6/50
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B desoxycholate (53.0%) or fluconazole (42.2%). The
overall mortality was 49.4%.
Non-Candida albicans species caused 78.9% of episodes of
candidaemia in patients with haematological malignan-
cies and 51.6% in those with solid tumours (p = 0.034).
The risk to have C. albicans as the aetiology of candidae-
mia for patients with solid tumours was 1.29 (CI 95%
1.03 to 1.61).
Table 1 shows the comparison of patients with haemato-
logical neoplasia and patients with solid tumours. At uni-
variate analysis, haematological patients were more
frequently exposed to corticosteroids and chemotherapy,
in comparison to patients with solid tumours. The per-
centage of neutropenic patients was much higher in the
haematological group – in fact, only 22.2% of patients
with solid cancers had candidaemia following an episode
of neutropenia. Age was also different between groups,
with a higher proportion of children in the haematologi-
cal group (47.4% versus 14.1%; p = 0.004). On the other
side, patients with solid tumours had required major sur-
geries more often, mainly in the gastrointestinal tract.
Median number of major surgical interventions for the
solid tumour group was 2.0 (mean 1.6, range, 1–6), and
median number of surgical procedures involving the gas-
trointestinal tract was 1.0 (range 1–5). Other risk factors
more commonly found in the solid tumours group were
ileus, use of anaerobicides, requirement of invasive
mechanical ventilation, urinary catheters, and admission
to the intensive care unit. Rates of antifungal therapy use
and mortality were similar between these two groups. At
Table 1: Major demographic features, predisposing conditions, antifungal treatment and outcome for patients with candidaemia and 
solid tumours or haematological malignancies (univariate analysis).
Variables Solid (%) Haematological (%) p value
Demographic factors
Age (median, years) 54.2 14.7 0.007c
Male sex 51.6 68.4 0.194a
Nosocomial infection 89.1 89.5 1.000b
Predisposing conditions
Neutropenia 22.2 78.9 < 0.001a
Duration of neutropenia (median, days) 5.0 17.0 0.004c
Mucositis 9.4 11.1 1.000b
Diarrhoea 29.7 21.1 0.460a
Ileus 34.4 5.6 0.016a
Corticosteroids 41.3 84.2 0.001a
Chemotherapy 29.4 84.2 < 0.001a
Previous stay in the intensive care unit 48.4 21.1 0.034a
Invasive medical procedures
Central venous catheter 75.0 89.5 0.221b
Implanted port 25.0 36.8 0.311a
Mechanical ventilation 35.9 0.0 0.002a
Urinary catheter 59.4 10.5 < 0.001a
Parenteral nutrition 21.9 5.3 0.172b
Haemodialysis 4.7 5.3 1.000b
Radiotherapy 9.4 5.3 1.000b
Major surgery 42.2 0.0 0.001a
Gastrointestinal surgery 23.4 0.0 0.018b
Antibiotic use
Duration (median, days) 13 15 0.996c
Number of antibiotics (median) 3 3 0.474c
Metronidazole or clindamycin 42.2 15.8 0.035a
4th generation cephalosporins 29.7 68.4 0.003a
Glycopeptides 37.5 57.9 0.114a
Carbapenems 12.5 15.8 0.708b
Breakthrough candidaemia 7.8 15.6 0.376b
Previous bactaeremia 28.1 47.4 0.116a
Antifungal treatment 73.4 84.2 0.542b
Death during hospitalization 53.1 36.8 0.213a
Total (n) 64 19 83
a Chi-square test; b Fisher's exact test; c Mann-Whitney test.BMC Infectious Diseases 2006, 6:50 http://www.biomedcentral.com/1471-2334/6/50
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Table 2: Univariate analysis comparing non-neutropenic adult patients with candidaemia and solid tumours (group 1) and adult 
patients with candidaemia and other diagnoses than cancer (group 2).
Variables Group 1 (%) Group 2 (%) p value
Demographic factors
Age (median, years) 62.0 59.8 0.828c
Male sex 56.5 54.0 0.791a
Nosocomial infection 87.0 87.3 0.958a
Diabetes mellitus 15.2 28.6 0.101a
Chronic renal failure 6.5 20.6 0.040a
HIV infection 0.0 7.9 0.072b
Heart failure 2.2 11.1 0.135b
Liver disease 2.2 9.7 0.235b
Chronic obstructive pulmonary disease 4.3 25.4 0.003a
Predisposing conditions
Transfusion of blood products 58.7 46.0 0.191a
Gastrointestinal bleeding 17.4 20.6 0.672a
Mucositis 6.5 0.0 0.072b
Diarrhoea 21.7 33.3 0.185a
Ileus 41.3 25.4 0.079a
Corticosteroids 28.3 46.0 0.060a
Previous bacteraemia 21.7 27.0 0.531a
Previous shock requiring vasopressors 23.9 31.7 0.371a
Previous stay in the intensive care unit 45.7 49.2 0.714a
Invasive medical procedures
Central venous catheter 82.6 63.5 0.029a
Implanted port 21.7 0.0 <0.001b
Nephrostomy 6.5 1.6 0.308b
Mechanical ventilation 41.3 46.0 0.623a
Jejunostomy 10.9 6.3 0.489b
Urinary catheter 69.6 57.1 0.186a
Enteral feeding 54.3 54.0 0.969a
Chest drainage 13.0 11.1 0.759a
Abdominal drainage 23.9 12.7 0.127a
Parenteral nutrition 28.3 19.0 0.258a
Haemodialysis 6.5 15.9 0.137a
Major surgery 50.0 39.7 0.284a
Gastrointestinal surgery 32.6 14.3 0.023a
Neurosurgery 0.0 3.2 0.508b
Cardiothoracic surgery 6.5 9.5 0.731b
At candidaemia
Shock requiring vasopressors 13.0 28.6 0.053a
APACHE II score (median) 15.0 16.5 0.742c
Concomitant bacteraemia 21.7 19.0 0.730a
Antibiotic use
Duration (median, days) 11.5 12.0 0.513c
Number of antibiotics (median) 3.0 3.0 0.337c
Metronidazole or clindamycin 43.5 27.0 0.072a
4th generation cephalosporins 34.8 31.7 0.739a
Glycopeptides 23.9 41.3 0.059a
Carbapenems 10.0 27.0 0.038a
Candida species
Candida albicans 60.9 49.2 0.227a
Candida parapsilosis 17.4 22.2 0.535a
Candida tropicalis 10.9 12.7 0.771a
Candida isolation from sites other than blood
Catheter 17.4 7.9 0.133a
Urinary 19.5 27.0 0.048a
Breakthrough candidaemia 6.5 4.8 0.696b
Antifungal treatment 71.7 71.4 0.972a
Death during hospitalization 58.7 55.6 0.744a
Total (n) 46 63 109
a Chi-square test; b Fisher's exact test; c Mann-Whitney test.BMC Infectious Diseases 2006, 6:50 http://www.biomedcentral.com/1471-2334/6/50
Page 5 of 7
(page number not for citation purposes)
multivariate analysis, the presence of ileus (OR 1.9; CI
95% 0.1 to 21.9) and use of anaerobicides (OR 1.2; CI
95% 0.2 to 6.5) were associated with a higher risk for can-
didaemia in patients with solid tumours. A significant
positive interaction between these variables was found.
Based on these results, we were interested to document if
patients with solid tumours had any particular risk factor
for candidaemia in addition to the risk factors presented
in other critically ill non-cancer patients. In order to do
that, we decided to compare two groups: (1) non-neutro-
penic adult patients with solid tumours and candidaemia,
and (2) all other adult patients with candidaemia seen in
our medical centre during the same period, with diag-
noses other than cancer. These groups were very similar.
Patients without cancer (group 2) had a higher frequency
of diagnoses such as chronic renal failure and chronic
lung diseases. Candida was more commonly isolated from
the urine in these patients. Severity of illness was compa-
rable between groups, as judged by the APACHE II score
and the proportion of patients with shock requiring ino-
tropic support. At univariate analysis (table 2), the only
variables more often found in group 1 were previous use
of CVC – particularly implanted ports – and surgery
involving the gastrointestinal tract. At multivariate analy-
sis, again these two variables were associated with a higher
risk for candidaemia in patients from group 1 (CVC: OR
1.9; CI 95% 0.8 to 6.4; gastrointestinal surgery: OR 3.1; CI
95% 0.1 to 57.0). The 95% confidence interval includes
the null hypothesis, possibly because of the low number
of patients in the groups of comparison. We found a sig-
nificant positive interaction between these variables.
Discussion
Several studies have revealed risk factors for candidaemia
amongst patients with cancer. Similar to other popula-
tions, the use of antibiotics is recognized as an important
predisposing feature, as well as the presence of CVCs, neu-
tropenia, surgery, parenteral nutrition, and corticosteroids
[3,8-10]. However, as stated before, most of these risk fac-
tors were characterised in studies centred in patients with
haematological malignancies. The main idea behind the
present study was to provide some data for patients with
solid tumours by comparing them with two other popula-
tions of patients with bloodstream Candida  infection:
patients with a malignant haematological disease and
patients with diagnoses other than cancer. And, in fact,
these populations appeared to be quite different regarding
risk factors for candidaemia.
Invasive fungal infections are a major threat for patients
with haematological malignancies. Furthermore, candi-
daemia is the most frequent bloodstream fungal infection
affecting these individuals. Since neutrophils and mono-
nuclear cells are very important to damage and kill yeast
cells, hyphae and pseudohyphae, patients with haemato-
logical neoplasms are particularly at risk for these infec-
tions. This increased risk can either be a consequence of
their underlying malignancy and/or the treatment for
their disease [11], which frequently includes corticoster-
oids. According to previous studies [3,12], our haemato-
logical patients with candidaemia received chemotherapy
more frequently than patients with solid tumours. In
addition, previous use of corticosteroids was also more
common in the haematological group. These data rein-
force the idea that neutropenia and therapy with steroids
are not crucial for the occurrence of candidaemia in
patients with solid tumours. In a series of 20 patients with
solid tumours and candidaemia treated with high-dose
regimens of fluconazole [13], only one had previous
chemotherapy. All patients had a CVC in place in that
study. Although international guidelines [1] have applied
the knowledge derived from patients with haematological
malignancies to patients with solid tumours in the treat-
ment of fever in patients with cancer, these populations
are very heterogeneous, and specific risk factors need to be
addressed to patients with solid tumours.
Different from other studies, which have found candidae-
mia more frequently in patients with haematological neo-
plasms [3,9,14], candidaemia in our institution occurred
mainly in patients with solid tumours. This may have
occurred because Santa Casa Complexo Hospitalar is a
referral hospital for these conditions. Unfortunately, no
denominator was available to calculate the incidence of
candidaemia in different populations. The finding that
patients with haematological malignancies were younger,
in comparison with patients with solid tumours, may also
just reflect the characteristics of patients treated in our
medical centre.
Similarly to previous studies [3,8,12], our findings suggest
that gastrointestinal surgery might be a predisposing fac-
tor to the development of candidaemia in patients with
solid tumours. Firstly, ileus and use of anaerobicides were
associated with a higher risk of candidaemia in patients
with solid tumours, in comparison to haematological
patients. Secondly, gastrointestinal surgery and the use of
CVC were independently associated with risk for candi-
daemia in non-neutropenic adults with solid tumours, in
comparison to other adult patients with candidaemia but
no cancer. A significant positive interaction was observed
for both comparisons, which means that patients who
had ileus also received more anaerobicides, and those
submitted to gastrointestinal surgery were also more fre-
quently treated with CVC. This could merely be a reflec-
tion of the higher proportion of patients with
gastrointestinal cancers in the solid tumour group, who
were – as expected – treated surgically. However, it is also
possible that the surgical trauma could have facilitated theBMC Infectious Diseases 2006, 6:50 http://www.biomedcentral.com/1471-2334/6/50
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translocation of these organisms to the bloodstream – in
this case, gastrointestinal surgery is to be an independent
risk factor for candidaemia in patients with solid tumours.
New studies will be required to confirm this hypothesis,
and to clarify if this is true only to patients with gastroin-
testinal cancers.
In accordance to the findings of Viscoli et al. [12], most of
the patients with solid tumours and candidaemia in our
study did not have metastatic disease, reinforcing the con-
cept that candidaemia do not occur only in patients with
advanced disease. The unexpected low frequency of fun-
doscopic examination amongst our cancer patients was
discussed elsewhere [15]. The overall mortality amongst
cancer patients with candidaemia was 49.4%, which was
in accordance to other studies [16-21].
Likewise previous studies [3,9,22,23], species other than
Candida albicans caused most episodes of candidaemia in
cancer patients in our study, mainly in patients with hae-
matological malignancies. The recognition of non-Cand-
ida albicans species as pathogens in oncology patients are
supposed to be the result of the widespread use of antifun-
gal agents in the early 1990's for prophylaxis after haemat-
opoietic stem-cell transplantation and as the treatment in
the setting of febrile neutropenia [24]. However, some
studies [9,25] have reported low use of azoles in Brazil,
suggesting that previous use of antifungals was not the
main factor associated with the emergence of non-Cand-
ida albicans species in these institutions. In fact, many
other factors seem to be implicated in the emergence of
these species, which discussion is beyond the scope of this
study. For instance, C. parapsilosis has been linked to the
widespread use of CVCs [6,19], and C. tropicalis has been
associated with cancer (especially neutropenia and
mucositis) even before the introduction of fluconazole in
clinical practice [9,26,27]. As previously showed [28],
Candida albicans was the dominant species in surgical
patients, as revealed for patients with solid tumours in
this study.
This study has some limitations. It is important to empha-
sise that some of the differences here described might be
related basically to differences in underlying diseases, as
we did not have a control group without candidaemia.
The lack of susceptibility tests is other drawback to be
mentioned. The retrospective nature of this study might
also have led to underestimation of important variables
such as the grade of mucositis. It should also be noticed
that the small number of patients included in this study
might have prevented some associations to reach statisti-
cal significance. Additionally, this fact might also have
influenced the interactions observed amongst variables in
multivariate model. Although some risk factors for candi-
daemia in patients with solid tumours were here identi-
fied, there is a clear need for new studies in the field.
Our main conclusions are that cancer patients with candi-
daemia seem to have different predisposing factors to
acquire the infection when stratified according to baseline
diseases. Whilst neutropenia and therapy with corticoster-
oids were important risk factors for patients with haema-
tological malignancies, multivariate analysis revealed that
ileus and the use of anaerobicides were independently
associated with candidaemia in patients with solid
tumours. In the comparison to patients with candidaemia
and diagnoses other than neoplasia, the performance of
gastrointestinal surgery and the presence of CVC were
found to be independent risk factors for candidaemia
amongst non-neutropenic adult patients with solid can-
cers. When looking at the 95% confidence intervals, one
might interpret the results as reflecting lack of association.
However, that would be a mistaken conclusion because
the likelihood of any given value of the true parameter
being estimated is not uniform across the range of values
contained in the confidence interval. The confidence
interval merely expresses the statistical uncertainty of the
point estimates. It is important to remember that statisti-
cal significance and the width of the confidence limits are
strongly dependent on the sample size. In this study, there
were few patients in some groups of comparison. In the
same way, there was a significant interaction between the
variables, meaning that the effects of the exposure on the
outcomes differ depending on whether another variable
(the effect modifier) is present. Interaction implies that
the variables should be considered together, not sepa-
rately. When interaction is present, the association
between the risk factor and the outcome variable differs,
or depends in some way on the level of the covariate, that
is, the covariate modifies the effect of the risk factor [7].
Following a worldwide trend, species other than C. albi-
cans were the main aetiology of candidaemia in this study.
However, the majority of non-neutropenic adult patients
with solid tumours had candidaemia caused by C. albi-
cans. Although these results help to identify patients with
solid tumours at higher risk for Candida  bloodstream
infections, large studies seem to be required to address
specific risk factors for candidaemia in this population.
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